同和药业(300636.SZ)：未来3-5年公司总产能有望达到20亿的规模

Core Viewpoint - The company, Tonghe Pharmaceutical, has indicated significant growth potential for its second-tier product lineup over the next 3-5 years, alongside ongoing registration of eight other products that will contribute to revenue [1] Group 1 - The company has 17 new products in its second-tier lineup that are expected to have substantial growth opportunities in the next 3-5 years [1] - The eight products currently in the registration process will gradually contribute to the company's revenue [1] - The total production capacity of the company is projected to reach 2 billion in the next 3-5 years [1]